UTEK Corporation and Haemacure Corporation announce a technology acquisition alliance


    TAMPA, FL and MONTREAL, QC, June 21 /CNW Telbec/ - UTEK Corporation
(AMEX & LSE-AIM: UTK), a specialty finance company focused on technology
transfer, and Haemacure Corporation (TSX: HAE), a specialty bio-therapeutics
company developing high-value human proteins, today announced the signing of a
technology acquisition alliance.
    "Haemacure is pleased to execute this technology acquisition alliance
with UTEK as we believe that it will provide Haemacure with global access to
intellectual properties that can leverage our product candidates," said Joseph
Galli, Chief Executive Officer of Haemacure.
    "UTEK looks forward to working with Haemacure to identify potential
technology acquisition opportunities that fit its strategic vision. This
alliance was entered into under UTEK's previously announced Master Alliance
Agreement with Rodman & Renshaw's Acumen Biofin division," commented Clifford
Gross, Ph.D., Chief Executive Officer of UTEK.
    Through its technology acquisition alliances, UTEK assists companies in
enhancing their new product pipeline with the acquisition of proprietary
intellectual capital from universities and laboratory research centers.
Technology acquisition alliances are generally cancellable by either party
with thirty days advance written notice.

    About Haemacure Corporation

    Haemacure Corporation is a specialty bio-therapeutics company developing
high-value human therapeutic proteins for commercialization. Haemacure's
research and development effort is driven by its proprietary plasma protein
extraction technology to develop next-generation products, including surgical
    Hemaseel(TM)HMN, Haemacure's lead product candidate, is a human-derived
fibrin sealant in late-stage clinical development. Haemacure's second product
candidate is human thrombin, a component of its fibrin sealant. Both
candidates have applications in the expanding bio-surgical market. Follow-on
development will focus on surgical haemostats, biomaterial combinations and
drug delivery in select therapeutic areas. Haemacure has recently discovered
additional specialty proteins in its plasma-derived intermediates and will
advance these specialty proteins through partnerships with other
pharmaceutical and biotechnology companies. For more information about
Haemacure please visit its website at www.haemacure.com.

    About UTEK Corporation

    UTEK(R) is a specialty finance company focused on technology transfer.
UTEK's services enable companies to acquire innovative technologies from
universities and research laboratories worldwide. UTEK facilitates the
identification and acquisition of external technologies for clients in
exchange for their equity securities. This unique process is called U2B(R). In
addition, UTEK offers companies the tools to search and analyze university
intellectual properties. UTEK is a business development company with
operations in the United States, United Kingdom and Israel. For more
information about UTEK, please visit its website at www.utekcorp.com.

    Forward-looking Statements

    Certain of the statements contained in this news release are
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown. Some examples of known risks are: the impact
of general economic conditions, general conditions in the biotech industry,
changes in the regulatory environment in the jurisdictions in which Haemacure
Corporation does business, stock market volatility, fluctuations in costs, and
changes to the competitive environment due to consolidation or otherwise.
Consequently, actual future results may differ materially from the anticipated
results expressed in the forward-looking statements. Haemacure Corporation
disclaims any intention or obligation to update these statements.

For further information:

For further information: UTEK Corporation: USA: Tania Bernier, (813)
754-4330 x 223; UK: Bankside Consultants: Steve Liebmann or Simon Bloomfield,
+ 44 (0) 20-7367-8883; Haemacure Corporation: Joseph Galli, Chairman and CEO,
(514) 990-7074; Gilles Lemieux, Investor Relations, (514) 282-3350 ext. 22,
Cel.: (514) 968-1382

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890